Sep 12, 2024, 17:16
Yüksel Ürün: Omitting the 5-FU bolus from regimens in metastatic GI cancers may reduce toxicity without impacting overall survival
Yüksel Ürün shared on X:
“Omitting the 5-FU bolus from regimens like FOLFOX, FOLFIRI, and FOLFIRINOX in metastatic GI cancers may reduce toxicity without impacting overall survival.”
Authors: Chengwei Peng, Saad Saffo, Paul E. Oberstein, Michael Shusterman, Charlene Thomas, Daniel J. Becker, Jordan D. Berlin, Lawrence P. Leichman, Ben Boursi, Anil B. Nagar, Shun Yu
Source: Yüksel Ürün/X
More posts featuring Yüksel Ürün on oncodaily.com
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 6, 2024, 17:35
Oct 6, 2024, 17:16
Oct 6, 2024, 17:12